TYRA | Ticker Profile - Titan Protect

TYRA

Tyra Biosciences, Inc.

Healthcare · Biotechnology · NMS

$26.64

Data: 2026-05-28

✗ ETHICAL FAIL

Unknown MOAT

MODERATE

Data Confidence: 71.4%

Key Metrics

How this company measures up on the fundamentals that matter

Market Cap

$2.0B

Total market value of the company

Trailing P/E

N/A

Forward P/E

-11.69

Based on estimated future earnings — lower means cheaper

Rev Growth

N/A

Year-over-year revenue change

Profit Margin

0.0%

How much profit the company keeps from each dollar of revenue

ROE

-36.9%

Return on equity — how efficiently it uses shareholder money

Analyst Target

$53.00

+99% from current price — median analyst estimate

Recommendation

STRONG_BUY

Consensus view from 11 analysts covering this stock

About Tyra Biosciences, Inc.

Tyra Biosciences, Inc., a clinical-stage biotechnology company, develops precision medicines for fibroblast growth factor receptor (FGFR) biology in the United States. The company offers SNÅP, a precision medicine platform that enables drug design through iterative molecular snapshots to predict genetic alterations for developing therapies targeting oncology and genetically defined conditions. Its lead product candidate is FGFR3, which is in clinical trials for the treatment of patients with metastatic urothelial carcinoma and other solid tumors. The company is also developing TYRA-300 for skeletal conditions, including achondroplasia, hypochondroplasia, dysplasia, and other FGFR3-driven genetic syndromes; TYRA-200, a candidate in clinical trial for intrahepatic cholangiocarcinoma; and TYRA-430 for the treatment of hepatocellular carcinoma. Tyra Biosciences, Inc. was incorporated in 2018 and is headquartered in Carlsbad, California.

https://tyra.bio

Country: United States Employees: 87 Industry: Biotechnology

Ethical Screening

Five compliance checks based on AAOIFI standards — all must pass for ethical clearance

Business Activity

PASS

Core business does not involve prohibited activities

Debt Ratio

0.0% N/A

Debt must be below 33% of total assets

Cash Ratio

0.0% N/A

Interest-bearing cash below 33% of assets

Receivables

0.0% N/A

Receivables below 49% of assets

Revenue Purity

0.0% N/A

Non-compliant revenue below 5% — any excess requires purification

Quantitative Intelligence

Statistical analysis of price behaviour, risk, and market regime — independent of fundamental data

Regime

MARKDOWN

Price trending down — defensive positioning

Sharpe Ratio

0.885

Good returns relative to risk taken

Kelly Fraction

0.0708

Suggested allocation is meaningful — the edge justifies a position

Calmar Ratio

0.577

Acceptable balance between returns and drawdown risk

Annual Return

43.5%

Historical annualised return based on price data

Max Drawdown

-75.3%

Largest peak-to-trough decline — the worst it has been

HMM State

SIDEWAYS

Price consolidating — no clear directional bias

Days in State

108

How long the current regime has persisted — longer means more stable

Market Data

Trading characteristics and market positioning

Beta

0.79

Less volatile than the market — more defensive

52W High

$40.65

34% below the year high

52W Low

$8.88

200% above the year low

Avg Volume

1,059,527

Average daily shares traded — higher means easier to buy and sell

Short Ratio

8.8

Days it would take all short sellers to cover — higher means more crowded

Short % Float

25.1%

Very high short interest — potential squeeze candidate

Div Yield

N/A

Annual dividend as a percentage of the share price

EPS (TTM)

$-2.18

Earnings per share over the last 12 months

Financial Health

Balance sheet strength and cash generation — the foundation of long-term value

Debt/Equity

1.47

Meaningful debt load — monitor closely

Current Ratio

20.49

Strong balance sheet — comfortably covers short-term obligations

Quick Ratio

20.05

Like current ratio but excludes inventory — stricter test

Gross Margin

0.0%

Revenue left after cost of goods — higher means pricing power

Operating Margin

0.0%

Profit from core operations before interest and tax

Free Cash Flow

$-60,137,752

Negative — the business is spending more than it generates

Revenue (TTM)

N/A

Total revenue over the last 12 months

Net Income

$-131,105,000

Loss-making — spending exceeds revenue after all costs

Analyst Coverage

Analysts

Target High

$59.62

Target Median

$53.00

Target Low

$37.00

Explore the Ethical Screener View Track Record

Data sourced from public filings and market feeds. Not financial advice. Updated: 2026-05-28

Before you go